Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00049400 · ClinicalTrials.gov registry record · Phase 1
S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction
A Phase 1 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
NCT00049400 is a Phase 1 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 78 participants.
The verdict
NCT00049400, a Phase 1 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of ixabepilone in treating patients with advanced solid tumors or lymphomas and liver dysfunction.
Interventions
- DRUG BMS-247550
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2003-10 |
| Est. Completion | 2007-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00049400
The ClinicalTrials.gov registry entry for NCT00049400 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMS-247550 is the first listed.
NCT00049400 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00049400 about?
NCT00049400 is a clinical study titled "S0355 Ixabepilone in Treating Patients With Advanced Solid Tumors or Lymphomas and Liver Dysfunction". RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of ixabepilone in treating patients with advanced solid tumors or lymphomas and liver dysfunction.
What is the current status of trial NCT00049400?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2003-10. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00049400?
The interventions under investigation include: BMS-247550 (DRUG).
Who is sponsoring clinical trial NCT00049400?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.